Your session is about to expire
← Back to Search
Virus Therapy
Flu Vaccine SD for Elderly Immune System
Phase 4
Waitlist Available
Led By Janet E McElhaney, MD
Research Sponsored by Health Sciences North Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up five years
Awards & highlights
Summary
This 5-year proposal is a randomized study of split-virus influenza vaccine (SVV) in a high-dose (HD) vs. standard-dose (SD) formulation in each of five influenza seasons to define the key determinants of vaccine-mediated protection against influenza and how these immunologic mediators may be enhanced by vaccination with a newly approved high-dose influenza vaccine in older people
Eligible Conditions
- Elderly Immune System
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ five years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~five years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Influenza Cases
Trial Design
2Treatment groups
Active Control
Group I: Flu Vaccine SDActive Control1 Intervention
Fluzone Standard Dose Influenza Vaccine
Group II: Flu Vaccine HDActive Control1 Intervention
Fluzone High Dose Influenza Vaccine
Find a Location
Who is running the clinical trial?
Health Sciences North Research InstituteLead Sponsor
10 Previous Clinical Trials
2,009 Total Patients Enrolled
UConn HealthOTHER
212 Previous Clinical Trials
60,704 Total Patients Enrolled
Janet E McElhaney, MDPrincipal InvestigatorHealth Sciences North Research Institute
Share this study with friends
Copy Link
Messenger